SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

BGE-102

BIOA·BioAge Labs, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Phase 2
Time to market
At least 3-5 years away. BGE-102 is in Phase 2; even with positive data, Phase 3 trials and FDA review would take several years. The QUELL-DME trial results are not expected until H2 2027.
Why 8/10
The next hard, dated catalyst is the QUELL-CV Phase 2 topline data readout, expected in Q4 2026 (imminent, within ~2 months). BGE-102 is BioAge's lead asset and drives most of the company's valuation. The stock has fallen ~79% from its 52-week high, making this binary readout a potential make-or-break event for the near-term thesis.
Actionable Insight BULLISH

The QUELL-CV Phase 2 topline data, expected in Q4 2026 (any day now through December), is the single most important catalyst. Positive data showing a clear dose-response on hsCRP and cardiometabolic biomarkers would validate BGE-102's best-in-class profile and likely drive a significant stock re-rating given the current depressed valuation. Negative or equivocal data would compound the sector skepticism from Novo Nordisk's failure and could pressure the stock further. QUELL-DME data in H2 2027 is a secondary catalyst.

Price Chart

Loading chart...

Executive Summary

BGE-102 is BioAge Labs' lead asset, a novel oral NLRP3 inflammasome inhibitor in Phase 2 development for cardiovascular risk reduction and diabetic macular edema. Phase 1 data showed 85% median reductions in hsCRP (a key inflammation biomarker), positioning it as a potential best-in-class oral therapy. The stock trades at $5.34, down ~79% from its 52-week high of $25.96, after a July 2026 selloff triggered by disappointing Novo Nordisk cardiovascular data that raised sector-wide concerns about NLRP3-targeting approaches. The imminent QUELL-CV Phase 2 topline readout (expected Q4 2026) is the defining near-term catalyst. Analyst consensus is strongly bullish (12 Buy-equivalent ratings, 4 Hold, 0 Sell) with a mean price target of $32.56, implying ~510% upside. The company holds $352.3M in cash, sufficient through 2029.

How It Works

BGE-102 is an oral small molecule that inhibits the NLRP3 inflammasome, a protein complex inside immune cells that triggers inflammation. By blocking this pathway, the drug aims to reduce harmful chronic inflammation implicated in cardiovascular disease, obesity, and diabetic eye disease. It is taken as a once-daily pill.

Trial Status

Two Phase 2 trials are active. QUELL-CV (cardiovascular risk) has completed enrollment with topline data expected in Q4 2026. QUELL-DME (diabetic macular edema) dosed its first participant in September 2026, with topline results expected in the second half of 2027. Phase 1 single/multiple ascending dose data showed 85% median hsCRP reductions at 60mg and 120mg once-daily doses in participants with obesity and elevated baseline inflammation, with good tolerability.

The Two-Sided Case

▲ Bull Case5
Phase 1 data showed 85% median hsCRP reductions, suggesting potential best-in-class oral NLRP3 inhibition
Analyst consensus is strongly bullish: 12 Buy-equivalent ratings vs 4 Hold, with a mean price target of $32.56 (510% upside from $5.34)
Strong institutional accumulation in Q2 2026: BlackRock, Geode, Goldman Sachs, JPMorgan, and Bank of America all added positions
Cash runway of $352.3M extends through 2029, eliminating near-term dilution risk
Oral once-daily dosing could be a significant advantage over injectable anti-inflammatory therapies if approved
▼ Bear Case5
Novo Nordisk's disappointing Phase 3 cardiovascular trial results in July 2026 sparked sector-wide skepticism about NLRP3-targeting therapies, causing BIOA stock to plunge
BGE-102 is still early-stage (Phase 2) with no proof-of-concept data yet in cardiovascular or retinal disease
QUELL-CV topline data could fail to show a clear dose-response or meaningful biomarker improvement
Net loss widened to $33.5M in Q3 2026 (from $20.2M a year earlier) as R&D spending rose 63%, and collaboration revenue declined 85%
Stock is in a bearish technical trend (SMA200 at $15.45 vs current $5.34, RSI 14 at 36.8, composite technical score of -29.5)

Upcoming Catalysts

  • QUELL-CV Phase 2 topline data expected Q4 2026 (imminent)
  • APJ agonist program IND submission on track for year-end 2026
  • QUELL-DME Phase 2 topline results expected H2 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BioAge Labs, Inc. PRESS-RELEASE BIOA ·Originating report

Sources · 9

Hover a chip for the title
1 biospace.com2 nasdaq.com3 finanznachrichten.de4 msn.com5 marketscreener.com6 sec.gov7 nasdaq.com8 morningstar.com9 ad-hoc-news.de